Zealand Pharma Valuation
Is ZEAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of ZEAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ZEAL?
Key metric:
| What is ZEAL's PB Ratio? | |
|---|---|
| PB Ratio | 5.8x |
| Book | DKK 8.88b |
| Market Cap | DKK 51.43b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 554.4x |
| Enterprise Value/EBITDA | -38.5x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ZEAL's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.4x | ||
GMAB Genmab | 2.8x | 21.4% | DKK 88.6b |
BAVA Bavarian Nordic | 1.5x | 3.4% | DKK 15.2b |
BIOPOR BioPorto | 7.5x | -27.8% | DKK 647.1m |
HLUN B H. Lundbeck | 1.8x | 9.3% | DKK 40.9b |
ZEAL Zealand Pharma | 5.8x | 39.1% | DKK 51.4b |
Price to Book Ratio vs Industry
How does ZEAL's PB Ratio compare vs other companies in the European Biotechs Industry?
| 26 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 26 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price to Book Ratio vs Fair Ratio
What is ZEAL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 5.8x |
| Fair PB Ratio | n/a |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 18:43 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zealand Pharma A/S is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Hindley | Berenberg |
| Kerry Holford | Berenberg |
| Charlie Haywood | BofA Global Research |